Obesity in Pediatric-Onset Multiple Sclerosis
A French Cohort Study

Pauline Milles, MD, Gianpaolo De Filippo, MD, Hélène Maurey, MD, Thomas Tully, PhD, and Kumaran Deiva, MD, PhD, on behalf of the KidBiosep

Neurol Neuroimmunol Neuroinflamm 2021;8:e1044. doi:10.1212/NXI.0000000000001044

Abstract

Objective
To study the link between a high body mass index (BMI) in childhood and the occurrence of pediatric-onset multiple sclerosis (POMS) and to compare, within the MS population, the clinical-radiologic-biological characteristics, according to BMI.

Methods
A case-control study comparing BMI data of 60 patients with POMS (39 girls and 21 boys) at Bicêtre Hospital with that of 113 non-neurologic controls NNCs (68 girls and 45 boys) and 18,614 healthy controls HCs (9,271 girls and 9,343 boys) was performed. Crude BMI (cBMI), residual BMI (rBMI = measured BMI – expected BMI for age), z-score (rBMI/SD), and adult equivalent categories (International Obesity Task Force ≥25 = overweight, ≥30 = obese) were assessed.

Results
In boys, cBMI and rBMI were significantly higher in patients with POMS compared with NNCs (cBMI: +2.9; rBMI: +2.95, p < 0.01) and HCs (cBMI: +2.04, p < 0.01). In girls, cBMI or rBMI did not differ between POMS and NNCs patients (cBMI p = 0.4; rBMI p = 0.44) but with HCs (cBMI +0.99, p < 0.01). CSF inflammatory markers increased with BMI in prepubertal patients (p < 0.01), whereas vitamin D level at diagnosis was lower in boys with higher BMI (p = 0.016). Increased BMI was not associated with clinical and radiologic disease characteristics.

Conclusions
Overweight and obesity are more frequently observed at diagnosis, particularly in boys with POMS compared with non-neurologic controls and French HCs. Moreover, BMI is related to initial inflammation in the CSF in prepubertal patients with POMS suggesting an interaction between excess body fat, sexual hormones, and POMS occurrence.
Multiple sclerosis (MS), a chronic inflammatory and autoimmune disease of the CNS, is the most common demyelinating disease in the world. Pediatric onset of MS (POMS) concerns 3%–10% of patients with MS and can occur before age 10 years in 1% of patients with MS.1–4 The annual incidence is 0.05–2.85 per 100,000 children depending on the country, and the patient’s sex ratio is balanced in childhood but becomes distorted toward females after puberty.5 A higher relapse rate is observed in children despite better recoveries after relapses, and a slower evolution toward a secondarily progressive disease has been described.6,7 POMS is probably the result of the interaction between genetic and environmental factors resulting in neuroinflammation. Among these factors, HLA DRB1*15:01,8–10 herpesviridae infections, particularly Epstein-Barr virus infection,11–15 vitamin D deficiency,16–18 diet and microbiota,19 and ethnic origin20 have been studied. An increasing but small number of studies on the potential link between childhood obesity and the occurrence of MS in children have emerged in recent years. The studies have conflicting results, but they seem to support the role of obesity in the occurrence of MS in the United States21–24 and in German populations.25 In France, body mass index (BMI) in the healthy pediatric population increased in the 1970s and 1980s, before stabilizing since the end of the 1990s. The prevalence of overweight and obesity is estimated to be, respectively, 13% and 4% (data from the national ESTEBAN study: Etude de Santé en Environnement, la Biosurveillance, l’Activité physique et la Nutrition, 2015). The relationship between POMS and obesity has not been studied yet. The causal role and mechanisms involved in obesity-mediated neuroinflammation remain unclear.

Low-grade inflammation mediated by obesity is thought to be able to lead to neuroinflammation via various mechanisms such as disruption of the blood-brain barrier (BBB) or primary activation of microglia in the CNS in response to adipokines released into the peripheral circulation by fatty tissues.26–28

Here, the first objective was to analyze the link between a high BMI in children, defining overweight and obesity, and the occurrence of POMS in the French pediatric population. Our second objective was to compare, in a French POMS group of patients, the clinical, biological, and radiologic characteristics between patients who were overweight or obese and those who had a normal BMI.

**Methods**

**Standard Protocol Approvals, Registrations, and Patient Consents**

The clinical and biological data of the patients came from the biobank of the national cohort of the first demyelinating episode KidBiosep 2004 (No. 910506), which has been authorized by the National Commission for Information and Liberties. An informed consent form was signed by the parents of each child included.

**Participants With MS**

Seventy-four patients with POMS (Figure 1), followed in the national referral center for rare inflammatory brain and spinal diseases and part of the national KidBiosep cohort, were included. The inclusion criteria were as follows: age <18 years at diagnosis of MS; diagnosed with MS between January 2010 and December 2018; and diagnosis of MS in accordance with IPMSSG criteria, 2013 criteria until 2017 and then with 2017 McDonald criteria. We decided to exclude from the analysis...

---

**Glossary**

BBB = blood-brain barrier; BMI = body mass index; CRP = C-reactive protein; FABP = fatty acid–binding protein; GLM = generalized linear model; IOTF = International Obesity Task Force; MS = multiple sclerosis; NNC = non-neurologic control; OCB = oligoclonal band; POMS = pediatric-onset MS; rBMI = residual BMI.

---

**Figure 1 Flowchart**

Criteria for inclusion:
- Diagnosis before age 18
- Krupp et al. (2013), McDonald criteria 2010 and 2017
- Diagnosis made between January 2010 and December 2018 at Bicêtre University Hospital

Non-neurologic controls (NNC) (n = 113):
- Patients hospitalized in adolescent medicine at CHU Bicêtre for various reasons without influence on BMI (113)

Patients (N = 74)

Excluded (n = 14):
- Lack of available data (height) before use of corticosteroid (13)
- Use of medications that could influence baseline BMI (1: oral corticosteroid for isolated clinical syndrome)

Healthy controls (HC) (n = 18,614)

Patients (POMS) (n = 60)
patients whose BMI at the first demyelinating episode (before any oral or IV corticosteroid treatment) was not available. We did not include patients who took other treatments likely to influence BMI (tricyclic antidepressants, neuroleptics, long-term corticosteroids, insulin, beta-blockers, sodium valproate, and lithium) or who had other concomitant pathologies likely to influence BMI such as respiratory diseases (asthma and cystic fibrosis), digestive (celiac disease and chronic inflammatory bowel disease), endocrine (diabetes, adrenal insufficiency, hypercorticism, and hypo or hyperthyroidism), neurologic disease other than multiple sclerosis, psychiatric difficulties (depression, anorexia nervosa, and bulimia), tumoral, genetic, nephrologic (tubulopathies), or cardiac problems (congenital heart failure). A total of 14 patients had to be excluded (n = 13/14 with lack of availability of height at diagnosis; n = 1/14 took oral corticosteroids for clinically isolated syndrome), based on the exclusion criteria detailed above (Figure 1).

**Control Groups**

**Non-neurologic Controls**
The local control group consisted of 113 patients younger than 18 years. Their clinical data had been collected during hospitalization in the Adolescent Medicine Department of Bicêtre Hospital between January 2014 and February 2019. They were subject to the same exclusion criteria as patients with POMS and were not expected to present any symptoms suggesting a demyelinating episode (reasons for consultation listed in eTable 2, links.lww.com/NXI/A516).

**Healthy Controls**
We finally used a data set on 18,614 healthy French children aged between 5 and 18 years as the second control group (providing 71,337 pairs of weight and height measurements). This healthy control (HC) group comes from various longitudinal studies conducted in France between 1981 and 2007 on the growth of the French pediatric population. We used this data set to model the mean corpulence (BMI) trajectories of healthy French boys and girls (data not shown), and these trajectories served as a reference against which to compare our patients with POMS and non-neurologic controls (NNCs).

**Data Collection**
The data were collected retrospectively (list of study variables in eTable 1 links.lww.com/NXI/A516). Weight was measured in kilogram (kg) and height in meter (m). BMI was calculated according to international recommendations (BMI = weight [kg]/height [m]²). The 3 International Obesity Task Force (IOTF) categories (normal, overweight, and obesity) were determined by plotting the patient’s BMI on adult equivalent curves according to international recommendations (IOTF). An IOTF of less than 25 indicated a BMI in the normal range; between 25 and <30 defined overweight, and equal to or greater than 30 defined obesity. When information on height at the time of the diagnosis was not available, it was extrapolated from the child’s height curve, comprising at least 3 points, or a curve consisting of at least 2 points framing the diagnosis period or, in rare cases, within 3 months before or after hospitalization.

For NNCs, data on date of birth, sex, weight, and height at hospital admission were collected. The BMI and IOTF categories were determined as for the patients with POMS. To calculate the residual BMIs (rBMIs) and z-scores, we first adjusted a generalized additive model (generalized additive model “gam” function) to model how BMI changes with increasing age for each sex in HC. Using smooth gam models allows us to describe the shape of the BMI age trajectories without having to make specific constrained hypotheses (these age trajectories are the black smooth lines on Figure 4). We then compared the measured BMI of NNCs and of patients with POMS with the BMI predicted with the gam models, given the age and sex of each patient, to compute the rBMI (rBMI = raw BMI − mean BMI of a healthy child of the same age and sex). To compute the z-scores, we divided the rBMI by the estimated standard deviance of the BMI of HC. For each POMS and NNC patient, we computed a standard deviance using a subset of the healthy children database that included the BMI measurements of healthy children whose age difference did not exceed 1.5 years compared with the patient. The patients who are more corpulent than an average healthy French child of the same age and sex have positive rBMI and z-score. Those who are leaner have negative rBMI and z-score. rBMI and z-score thus provide 2 (highly correlated) quantitative measurements of the patient’s corpulence relative to its pediatric fellow citizen while controlling for its sex and age. Table 1 summarizes the main characteristics of the 3 groups of children.

**Statistical Analysis**
Statistical analyses were performed using R 4.0.3 software, and we used the ggplot2 and visreg packages to generate the figures showing the models’ predictions. We first analyzed the BMI to search for any effect of sex and child type (POMS, NNC, and HC) with a generalized additive model (gam), which enabled to take into account the fact that BMI depends on an unknown nonlinear function of age (smooth term). We then completed this analysis with generalized linear models (GLMs, Gaussian) to quantify if and how the rBMI and z-score differed among our 4 groups of patients (POMS and NNC, boys and girls). The 3 IOTF categories were analyzed with binomial glm models to study the potential influence of sex and patient type (POMS vs NNC) on the probability to belong to each of these categories. More specifically, we analyzed if and how the probability that a child had an IOTF higher than 30 (resp. 25) was determined by its sex, age, and state (POMS vs NNC) using binomial model. Linear models (GLM) were used by applying Gaussian models for continuous variables, binomial models for binomial variables, and Poisson or quasi-Poisson models for discrete positive variables corresponding to counts. The BMI trajectory of some of the children in the cohort was also observed to define the anteriority of obesity. In the second part of the study, the
effect of BMI on various clinical, biological, and radiologic POMS variables was studied within the POMS patient cohort. Statistical tests used for each variable of the study and p values are detailed in eTables 1, 3, and 4 (links.lww.com/NXI/A516). The annual rate of clinical relapses, age at diagnosis, symptom at diagnosis, C-reactive protein (CRP) and vitamin D levels, presence or absence of contrast enhancement on initial MRI, number of T2 lesions on initial MRI, presence of inflammation on the initial CSF, and delay with the second relapse were analyzed as a function of sex, age (except for age at diagnosis), and rBMI at diagnosis.

Data Availability
Anonymized data will be shared by request from any qualified investigator.

Results
Data from 60 patients (39 girls and 21 boys, mean age 13.46 [12.8–14.1] years) diagnosed with MS before age 18 years were analyzed. They were compared with NNCs (68 girls and 45 boys, mean age 13.8 [13.3–14.3]) years] and with a larger group of HCs (9,271 girls and 9,343 boys) (Table 1).

Body Mass Index
We first studied whether the BMI differed among the 3 types of children (POMS, NNC, and HC). This model shows that BMI varies with age and is also affected by an interaction between child’s sex and type (Figure 2A). The Fisher statistics with 2 degrees of freedom for this sex × type interaction equal 9.1. The p value derived from comparing this F statistics to the Fisher distribution equals 0.0001. We express this as F2,df = 9.1, p < 0.001). The boys with POMS had on average a higher BMI than the NNCs (+2.9 BMI, F1 = 10, p < 0.001) and healthy boys (+2.06, F1 = 26, p < 0.001). We also found that the NNCs had a slightly lower BMI than the HCs (+1.1 BMI, F1 = 26, p < 0.001). Only boys with POMS were significantly different from zero (p = 0.19), but we found that the girls with POMS were on average slightly more corpulent that the healthy ones (+0.99, F1 = 8.7, p < 0.01) (Figure 2A).

rBMI and Z-Score
We found significant interaction between sex and patient type (POMS vs NNC) for both z-score (likelihood ratio $\chi^2$ value of 3.84 for 1 degree of freedom, expressed as $\chi^2 = 3.84, p = 0.049$) and rBMI ($\chi^2 = 3.73, p = 0.05$). Boys with POMS had a higher rBMI (+2.95) and z-score (+0.84) than the NNCs ($\chi^2 = 10.2, p = 0.0013$, Figure 2C), whereas this was not the case for girls ($p > 0.44$). Only boys with POMS had an rBMI significantly different from zero ($p = 0.007$), zero corresponding to HCs. They had an average BMI +2.19 points higher than an average healthy French boy of similar age (Figure 2B).

IOTF Categories
The probability of being obese was also found to depend on a sex × patient type interaction (IOTF ≥30, $\chi^2 = 4.23, p = 0.039$,
Figure 2 Effects of Sex and Children Type on BMI

Panel A presents the BMI predicted by the gam model for each combination of sex and children type, with predictions (horizontal blue lines) and their 95% CIs for a 13-year-old child. Panel B represents the BMI in terms of difference between the patient's BMI and the expected BMI of a HC (rBMI). The mean $z$-scores, which correspond to the rBMI divided by the SD of the BMI of HC, are presented on panel C. BMI = body mass index; HC = healthy control; NNC = non-neurologic control; POMS = pediatric-onset multiple sclerosis; rBMI = residual BMI.

This figure presents on the panel A the BMI predicted by the gam model for each combination of sex and children type. To control for the effect of patients' age, we present the predictions (horizontal blue lines) and their 95% CIs for a 13-year-old child. The panel B represents the BMI in terms of difference between the patient's BMI and the expected BMI of a HC (rBMI). The mean $z$-scores, which correspond to the rBMI divided by the SD of the BMI of HC, are presented on panel C. BMI = body mass index; HC = healthy control; NNC = non-neurologic control; POMS = pediatric-onset multiple sclerosis; rBMI = residual BMI.
The percentage of obese girls was similar among patients with POMS (10%) and NNCs (7.3%, \( p = 0.6 \)), but more obese children were observed among the boys with POMS (9.5%) than among the NNC boys (0%, \( \chi^2 = 14.3, p < 0.001 \)). When we included the overweight children (IOTF ≥ 25), the sex × patient type interaction was not significant anymore, and we found that on average, the children with POMS (boys and girls) were more likely to be overweight or obese than the NNCs (52% vs 18%, \( p = 0.01 \), Figure 3).

The BMI age trajectories of some children with POMS who have been followed several years before their first hospitalization have been plotted on Figure 4 to verify whether their weight status (being overweight or obese) occurs earlier in life: overweight, when it was present, occurred mostly before age 6 years, and increased in most cases in the peripubertal period.

Clinical, Biological, and Radiologic Characteristics of the Patients With POMS

In the patients with POMS, the clinical, biological, and radiologic characteristics of the disease were studied according to patients’ sex, rBMI, and age at diagnosis (models in eTable 4, links.lww.com/NXI/A516). The presence of oligoclonal band (OCB) in the CSF at diagnosis did not vary among sex but depended on an interaction between rBMI and age at disease onset (\( \chi^2 = 9.8; p = 0.0017 \)): in children younger than 14 years, the probability of observing an OCB increased in overweight children, whereas this effect disappeared for patients older than 14 years (Figure 5, eTable 4). Among the available data on OCBs (65% of patients), 74.3% of patients had OCBs at diagnosis, whereas 25.7% did not. Concerning proteinorachia in the CSF, there was no association between hyperproteinorachia and body weight.
**Figure 5** Presence of OCBs and Inflammation in the CSF

The 2-dimensional density plots (A and C) represent the prediction from the models age × rBMI interaction. The probability to observe an OCB (A) or any other marker of inflammation (pleocytosis and/or hyperproteinorachia and/or OCBs) (C) increases with the patient’s corpulence in a prepubertal child (aged <14 years) but not in older patients. The panels B and D represent the model prediction for an 11-year-old patient (underlined with the dotted blues lines in panels A and C). OCB = oligoclonal band; rBMI = residual body mass index.
(rBMI) in boys ($\chi^2_1 = 1.22$, $p = 0.27$), whereas in girls, the probability of observing a hyperproteinorachia increased with rBMI ($\chi^2_1 = 9.34$, $p = 0.002$, Figure 6, eTable 4). The probability of observing any of the 3 markers of inflammation (hyperproteinorachia and/or pleocytosis and/or OCB) was similar for both sexes ($p = 0.95$). It increased with rBMI but only in younger children ($<14$ years, $\chi^2_1 = 7.17$, $p = 0.007$, Figure 5). Results were available for 81.7% of patients with POMS for hyperproteinorachia and pleocytosis. The mean vitamin D level at onset measured in patients with POMS was 19.4 ng/mL, corresponding to vitamin D deficiency. The values were measured in 60% of patients and ranged from 5 to 41.2 ng/mL. Vitamin D levels at onset decreased with increasing corpulence in boys ($\chi^2_1 = 5.75$, $p = 0.016$) but did not vary significantly with girls’ rBMI ($p = 0.62$, Figure 6, eTable 4). Time interval between the first 2 relapses, probability to have more than 7 T2 lesions, and probability to have a gadolinium enhancement (at least 1 contrast-enhancing lesion) on initial MRI did not differ significantly according to patient rBMI ($p = 0.47$, eFigure 1, links.lww.com/NXI/A515, and eTable 4). Data concerning time interval before the second relapse were available for 100% of patients, about initial MRI for 80% of patients for number of lesions, and 75% for gadolinium enhancement.

The age at diagnosis, annualized relapse rate, first clinical signs, and CRP levels at diagnosis did not vary significantly according to the patient's corpulence, sex, or age at diagnosis (data not shown).

**Discussion**

We observed a higher prevalence of overweight and obesity in our sample of French patients with POMS at diagnosis, and one of our findings is the possible sexual dimorphism, attributing a higher risk to male sex. We have also noticed that overweight and obesity were associated with a higher probability to observe CSF inflammatory markers in younger patients. A particularity of this study is to have used 2 control groups. The first one (NNC) included children and

---

**Figure 6 Effect of POMS Patients’ Corpulence on Hyperproteinorachia and Vitamin D Levels**

**A. Hyperproteinorachia and corpulence**

- **Boys**
  - $\chi^2_1 = 1.22$, $p = 0.27$
- **Girls**
  - $\chi^2_1 = 9.34$, $p = 0.002$

**B. Vitamin D and corpulence**

- **Boys**
  - $\chi^2_1 = 5.75$, $p = 0.016$
- **Girls**
  - $\chi^2_1 = 9.34$, $p = 0.002$

(A) Predicted probabilities (black lines with 95% CI) of observing hyperproteinorachia (>0.4 g/L) as a function of corpulence (rBMI) at the first hospitalization for boys (nonsignificant effect of rBMI) and girls (the probability increases with patient's corpulence). (B) The vitamin D concentration (ng/mL) decreases with increasing corpulence in boys (black line with 95% CI, prediction from the model) but remains roughly constant in girls. The raw measurements are overlayed, and geometric shapes with different colors represent each patient's IOTF categories. IOTF = International Obesity Task Force; rBMI = residual body mass index; POMS = pediatric-onset multiple sclerosis.
adolescents followed in the Adolescent Medicine Department at Bicêtre Hospital. The second one was a large sample of the general healthy French pediatric population (HC). This allowed a double analysis and freed us from a selection bias or a lack of representativeness of the local control patient population.

The difference in prevalence of overweight/obesity was consistent whether expressed in terms of crude BMI to prevent the loss of raw information, corrected BMI called the residual BMI in this study, or the IOTF category. This study used the IOTF corresponding to the International Classification of Obesity and Overweight in children. This difference in prevalence was also found in girls with POMS, in whom there was a clear trend toward overweight and obesity at diagnosis, especially compared with HCs. The high prevalence of obesity and overweight at the time of diagnosis of MS has been observed in recent years in various studies, but it has never been reported in the French population. In California, obesity, and more specifically extreme obesity, has been found to be associated with MS, but contrary to our finding, it was observed in girls but not in boys. Obesity and overweight were characterized according to percentiles and gross BMI, without controlling for patients’ age, or referring to adult IOTF curves. In another US study, the BMI and proportion of overweight or obese were higher in MS cases than in controls for both girls and boys, but these differences were reported to be stronger for girls, although the interaction between sex and corpulence was not specifically tested. Brenton et al. reported that the interaction was more pronounced in boys than girls, when studying gross BMI before and at diagnosis of MS in the prepubertal, and postpubertal periods. A study that dissociates diagnosis in the prepubertal and postpubertal periods might be of interest if we consider the fact that hormonal status can potentially play a role in the development of POMS. A study that dissociates diagnosis in the prepubertal and postpubertal periods might be of interest if we consider the fact that hormonal status can potentially play a role in the development of POMS. In California, obesity, and more specifically extreme obesity, has been found to be associated with MS, but contrary to our finding, it was observed in girls but not in boys. Obesity and overweight were characterized according to percentiles and gross BMI, without controlling for patients’ age, or referring to adult IOTF curves.

In our study, BMI age trajectories of some patients suggest that overweight and obesity, particularly in boys, precede disease onset and occur in early childhood. Mouse models support the hypothesis that the low-grade inflammatory state mediated by obesity and increased leptin in obese males could be responsible for testosterone depletion via downregulation of kisspeptin neurons and inhibition of the gonadotropin axis. Testosterone, known for its anti-inflammatory actions at the cerebral level, through its depletion during puberty, could explain the stronger association in our study between POMS and obesity in boys. In adult men with MS, testosterone depletion is associated with increased disease severity and neuroinflammation progression. Our results on the sex × patient type interactions have to be interpreted with caution, and these hypotheses need to be explored in other studies.

Several hypotheses have been put forward as to the genesis of obesity-mediated neuroinflammation. This first hypothesis would support the theory of migration of self-reactive lymphocytes produced in the periphery by adipose tissue. A recent study has shown the involvement of the BBB in neuroinflammation in obese mice (leptin receptor deficient). By using a protein kinase inhibitor protein kinase C β that enhances the BBB, neuroinflammation was significantly reduced. In addition, pericytes can produce proinflammatory mediators leading to a defect in the permeability of the BBB in a porcine model. Another hypothesis concerning obesity-mediated neuroinflammation could be a massive activation of the different cell types present in the CNS in response to changes in peripheral levels of certain mediators such as leptin and other adipokines. Adult studies have shown high plasma levels of leptin, resistin, fatty acid–binding protein (FABP), and low levels of adiponectin in patients with relapsing-remitting MS. In children, 1 study found that serum leptin and FABP levels were negatively correlated with the hazard of relapse and disability score, whereas adiponectin levels were negatively correlated with these parameters. Further studies are needed to deepen our understanding of POMS.

Clinical, biological, and radiologic comparative study in children with MS according to their BMI demonstrated that vitamin D deficiency in girls was notTable regardless of BMI, whereas in boys, mean vitamin D levels at onset decreased with BMI. These observations echo the various findings that vitamin D deficiency is a potential risk factor in the pathogenesis of POMS. Our results showed that hyperproteinorachia (>0.4 g/L) and OCBs presence were significantly associated with BMI in younger children only. Results were the same by coupling the 3 markers of CSF inflammation (hyperproteinorachia and/or pleocytosis and/or presence of OCB): the probability of observing a sign of inflammation increased with corpulence but only in younger children less than 14 years. The relationship with puberty was little studied in our analysis. A study that dissociates diagnosis in the prepubertal and postpubertal periods might be of interest if we consider the fact that hormonal status can potentially play a role in the development of POMS, as raised in several studies.

The study limitations are a lack of power, related to sample size, but this is inherent to the fact that POMS is a rare disease in children. Interactions must be interpreted with caution given the sample size, and larger-scale studies are needed to confirm these results and clarify the role of sex hormones. In addition, the retrospective nature of the study resulted in a possible loss of information. This could explain the lack of significance in the girl subgroup.

In conclusion, overweight and obesity are observed more frequently in boys with POMS at the time of diagnosis.
compared with a local control population (NNC) and the healthy French pediatric population (HC). Excess body fat appears to influence initial inflammation in the CSF in prepubertal patients, but would not influence the annual relapse rate, the age of diagnosis of the pathology, or the initial clinical and radiologic parameters. Studies considering the hormonal influence of puberty would be necessary. These results need to be validated in prospective cohorts and highlight the importance of primary prevention of overweight and obesity in children, possibly involved in the processes of neuroinflammation.

**Study Funding**
No targeted funding reported.

**Disclosure**
P. Miles, G. de Filippo, H. Maurey, and T. Tully report no disclosures relevant to the manuscript. K. Deiva participates in treatment studies in pediatric MS led by Novartis, Sanofi-Genzyme, and Biogen and received consultation fees from Novartis, Alexion, Viala, and Sanofi-Genzyme. Go to Neurology.org/NN for full disclosures.

**Publication History**
Received by *Neurology: Neuroimmunology & Neuroinflammation* April 6, 2021. Accepted in final form May 26, 2021.

### Appendix 1 Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pauline Milles, MD</td>
<td>Bicêtre Hospital, Le Kremlin-Bicêtre, France</td>
<td>Substantial contributions to conception and design; acquisition, analysis, and interpretation of data; and drafting the article and/or revising it critically</td>
</tr>
<tr>
<td>Gianpaolo De Filippo, MD</td>
<td>Robert Debre Hospital, Paris, France</td>
<td>Revising the article critically and final approval of the version</td>
</tr>
<tr>
<td>Hélène Maurey, MD</td>
<td>Bicêtre Hospital, Le Kremlin-Bicêtre, France</td>
<td>Revising the article critically and final approval of the version</td>
</tr>
<tr>
<td>Thomas Tully, PhD</td>
<td>UMR7618, Sorbonne University, Paris, France</td>
<td>Revising the article critically and final approval of the version</td>
</tr>
<tr>
<td>Kumaran Deiva, MD</td>
<td>Bicêtre Hospital, Le Kremlin-Bicêtre, France</td>
<td>Substantial contributions to conception and design; acquisition, analysis, and interpretation of data; and drafting the article and/or revising it critically</td>
</tr>
</tbody>
</table>

### Appendix 2 Coinvestigators

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claire Bilbaut, MD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire de Nancy, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Daniel Amsellem, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Besançon, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Caroline Paris, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Besançon, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Anne-Lise Poulat, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Lyon, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Anne Lepine, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Marseille, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Pierre Meyer, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Montpellier, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Jean-Michel Pedespan, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Bordeaux, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Marie-Anne Barthez, MD</td>
<td>Neuro-inflammatory Competence Centre, Centre Hospitalo-Universitaire de Tours, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Patrick Van Bogaert, MD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Angers, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Chouchane Monderer, MD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Dijon, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Emmanuel Cheuret, MD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Toulouse, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Diana Rodriguez, MD, PhD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Trouseau, Paris, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Isabelle Desguerre, MD, PhD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Necker, Paris, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
<tr>
<td>Odile Boeufsflug-Tanguy, MD, PhD</td>
<td>Neuro-inflammatory Disease, Centre Hospitalo-Universitaire Debré, Paris, France</td>
<td>Following centers from the KidBiosep study</td>
<td>Collection and data sharing</td>
</tr>
</tbody>
</table>

### References